Skip to main content
. Author manuscript; available in PMC: 2022 Jan 1.
Published in final edited form as: Arterioscler Thromb Vasc Biol. 2020 Dec 3;41(1):e33–e45. doi: 10.1161/ATVBAHA.120.315154

Figure 2. Role of GPR31 (G-protein–coupled receptor 31) in thrombin-mediated human platelet aggregation.

Figure 2.

A, Effect of 5, 10, and 20 μmol/L 12(S)-HETE or 5 μM ADP (in red) on platelet aggregation using human platelet-rich plasma. B, Human platelets were preincubated for 2 min with 0, 3, and 10 μmol/L GPR310 (G-protein–coupled receptor 310) and 30 μmol/L ML355 before the addition of 160 μmol/L AYPGKF, and aggregation was assessed at 15 min. C, Gel-purified human platelets stimulated with 3, 10, and 30 μmol/L SFLLRN in the presence of 3 and 10 μmol/L GPR310 or 30 μmol/L ML355 as indicated. D, Platelet for ATP secretion was measured in gel-purified human platelets stimulated with indicated concentrations of AYPGKF and SFLLRN in the presence of 3 μmol/L GPR310 and vehicle. E, Platelet aggregation stimulated with 10 μg/mL collagen in the presence or absence of 3 μmol/L GPR310 or 30 μmol/L ML355. F, Platelets were stimulated with 10 nmol/L thrombin (T) in the presence of 3 μmol/L GPR310, 30 μmol/L 12-LOX (12-lipoxygenase) inhibitor (12-LOX-Inh; ML355), and 10 μmol/L P2Y12 ADP receptor Inh (AZD1283) as indicated. ANOVA followed by Bonferonni correction; *P<0.05, **P<0.01, ***P<0.001, unpaired 2-tailed t test.